© Drug Hunter Inc. 2018-2023
Home > BMS-986260
selective TGFβR1 kinase inhibitor
completed oral CV studies in higher species
from data mining of internal matter and opt.
ACS Med. Chem. Lett. 11, 172-178
Bristol-Myers Squibb, Princeton, NJ
BMS-986260 (Bristol Myers Squibb (BMS) oral in vivo selective TGF-beta-R1 kinase inhibitor)
Drug Hunter is commited to helping industry innovators make informed decisions. Premium members have access to our library of the latest stories in science, written by scientists.
Request a trial to access insights powering the pros in our industry.
Molecules of the Month
Molecule of the Year